{"id":764221,"date":"2023-06-15T17:07:54","date_gmt":"2023-06-15T21:07:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/"},"modified":"2023-06-15T17:07:54","modified_gmt":"2023-06-15T21:07:54","slug":"rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/","title":{"rendered":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BRIDGEWATER, N.J., June  15, 2023  (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the \u201cRules\u201d) at the Company\u2019s Annual General Meeting held on June 15, 2023 (the \u201cAGM\u201d).<\/p>\n<p>At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company\u2019s major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll. The result of the poll was 36,568,508 votes for; and 390,152 votes against. There were 2,245,474 abstentions or withheld votes.<\/p>\n<p>Accordingly, the aggregate percentage shareholding in the capital of the Company held by the parties specified in the table below (and persons deemed to be acting in concert with them under the Rules) (together, the \u201cAffected Parties\u201d) may proportionally increase up to the maximum percentage specified below in the event of the issue by the Company of up to 17,000,000 new ordinary shares, US $0.01 nominal value per share, in the capital of the Company. In such circumstances, the Affected Parties will not incur an obligation under Rule 9 of the Rules to make a general offer to the Company&#8217;s other shareholders.<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:55%;width:55%;min-width:55%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>March 31, 2023 <br \/>Shareholding\u00a0<br \/><\/strong><br \/>\n            <strong>(Number)<\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>March 31, 2023 <br \/>Shareholding\u00a0<br \/><\/strong><br \/>\n            <strong>(%)<\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>Potential <br \/>Shareholding\u00a0<br \/><\/strong><br \/>\n            <strong>Following <br \/>Share Issues\u00a0<br \/><\/strong><br \/>\n            <strong>(%)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Avista Healthcare Partners, L.P.<\/strong><br \/>\n            \n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: top\">23,730,864 ordinary shares<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">23.89%<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">29.56%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Altchem Limited and Orbit Co-Invest A-1 LLC<\/strong><br \/>\n            \n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: top\">23,667,540 ordinary shares<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">23.82%<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">29.50%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Management Individuals (as defined in the Proxy Statement)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: top\">3,086,261 ordinary shares<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">3.11%<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">4.07%<\/td>\n<\/tr>\n<\/table>\n<p>The full text of the resolution (being Proposal 3) is set out in the Proxy Statement in respect of the AGM which is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ow243gVg-MeX2bB1bnTZcZDRlcmdpRfRmHuudCaWxC1v5JBapKDIedexjJPNNBW3S_Z2KNgCKCaIWZxKo97E_Maqio-M4Ahny14tTma0wMFUhSzwAOjo570vS5fh4Dqhpk86J4Xh3F50IiFRnRFq-YO3xjLl_aZr2OnfkOTjJsionZ6uENo4d23pYMwQj6j-BwKoOR9CYcxNmdpF4Cv1ZKiQvHmgjBosUERYt2zbbMcl32vOEWcKbQhIOlQh9DOQo4znlhppQFBheaVqwifidw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.rvlpharma.com<\/a>.<\/p>\n<p>\n        <strong>About RVL Pharmaceuticals plc<\/strong><\/p>\n<p>RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ\u00ae (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids, in adults. UPNEEQ is the first non-surgical treatment option approved by the U.S. Food and Drug Administration for acquired blepharoptosis.<\/p>\n<p>\n        <strong>Investor and Media Relations for RVL Pharmaceuticals plc<\/strong><\/p>\n<p>Lisa M. Wilson<br \/>In-Site Communications, Inc.<br \/>T: 212-452-2793<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=McO_DMKo6YyNphRpz6OI9mP_X01NkVKztM9dZ7PtAJcmcpVTZup_0JAt2Ksgtg6z9HzX7Ep-bDlOMSHW8HeRA35D4IE-ixZTCOdj7mz5omChxz4j3KD4dEYvTBhp4CJmwBSDMiynXs8sqOVTzwTLAPgEjC33tAKFYU31IF3_Lfp1rp2LpLOY8bsddvcDmMO4-my0jbvK66Dk9bkUQSKeVQY6lqZjT54Je4E_7JNtNdLnpBR-183aRZt41TxUg-ZII3YXHJ1lL2RjIH4Xs2dUGw==\" rel=\"nofollow noopener\" target=\"_blank\">lwilson@insitecony.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzNlYjk3ZTUtYzhjNC00Y2Q3LWEzZWQtNThkY2Y2ZGRiN2JkLTExMDk0NTA=\/tiny\/RVL-Pharmaceuticals-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the \u201cRules\u201d) at the Company\u2019s Annual General Meeting held on June 15, 2023 (the \u201cAGM\u201d). At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company\u2019s major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll. The result of the poll was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-764221","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the \u201cRules\u201d) at the Company\u2019s Annual General Meeting held on June 15, 2023 (the \u201cAGM\u201d). At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company\u2019s major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll. The result of the poll was &hellip; Continue reading &quot;RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-15T21:07:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting\",\"datePublished\":\"2023-06-15T21:07:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/\",\"name\":\"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\",\"datePublished\":\"2023-06-15T21:07:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/","og_locale":"en_US","og_type":"article","og_title":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk","og_description":"BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the \u201cRules\u201d) at the Company\u2019s Annual General Meeting held on June 15, 2023 (the \u201cAGM\u201d). At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company\u2019s major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll. The result of the poll was &hellip; Continue reading \"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-15T21:07:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting","datePublished":"2023-06-15T21:07:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/"},"wordCount":390,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/","name":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=","datePublished":"2023-06-15T21:07:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMyMiM1NjUwNDcxIzIwOTc4Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-announces-result-of-proposal-to-approve-a-waiver-of-offer-obligations-under-rule-9-of-the-irish-takeover-rules-at-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/764221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=764221"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/764221\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=764221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=764221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=764221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}